Cargando…

An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting

INTRODUCTION: The primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band l...

Descripción completa

Detalles Bibliográficos
Autores principales: Bañares, Rafael, Albillos, Agustín, Nakum, Mitesh, Gea, Salvador, Varghese, Angel, Green, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272260/
https://www.ncbi.nlm.nih.gov/pubmed/37160834
http://dx.doi.org/10.1007/s12325-023-02517-x
_version_ 1785059455978700800
author Bañares, Rafael
Albillos, Agustín
Nakum, Mitesh
Gea, Salvador
Varghese, Angel
Green, William
author_facet Bañares, Rafael
Albillos, Agustín
Nakum, Mitesh
Gea, Salvador
Varghese, Angel
Green, William
author_sort Bañares, Rafael
collection PubMed
description INTRODUCTION: The primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band ligation plus drug therapy. Secondly, to treat refractory ascites (indication 2) compared with large volume paracentesis. METHODS: A two-state (alive and dead) Markov model was developed to capture the costs and health impact for the two indications over a 2-year time horizon with monthly cycles. In the alive state, patients could experience adverse event(s), associated with costs and disutility, such as recurrent variceal bleeding, ascites, and hepatic encephalopathy. Discount rates of 3% for utilities and costs and a cost-effectiveness threshold of €25,000 per QALY were applied. RESULTS: In the base case analysis, TIPSS was estimated to be cost-effective as a pre-emptive treatment for indication 1 (incremental cost and QALYs of − €230 and 0.211, respectively). TIPSS also remained cost-effective (€16,819/QALY) in a conservative scenario analysis, conducted with an alternate source for clinical parameters. The key drivers of the outcomes were survival for the comparator arm, mean band ligation outpatient procedures, and TIPSS treatment costs. TIPSS was estimated to dominate the comparator for indication 2 (incremental cost and QALYs of − €25,687 and 0.531, respectively). The key drivers of the outcomes were monthly paracentesis sessions and cost per inpatient stay for those undergoing paracentesis. CONCLUSIONS: TIPSS is likely to be a cost-effective and a cost-saving treatment in patients with cirrhosis in indications 1 and 2, compared with standard treatments. The analyses estimate clinical benefits along with reduced healthcare costs from avoided downstream resource consumption. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02517-x.
format Online
Article
Text
id pubmed-10272260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-102722602023-06-17 An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting Bañares, Rafael Albillos, Agustín Nakum, Mitesh Gea, Salvador Varghese, Angel Green, William Adv Ther Original Research INTRODUCTION: The primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band ligation plus drug therapy. Secondly, to treat refractory ascites (indication 2) compared with large volume paracentesis. METHODS: A two-state (alive and dead) Markov model was developed to capture the costs and health impact for the two indications over a 2-year time horizon with monthly cycles. In the alive state, patients could experience adverse event(s), associated with costs and disutility, such as recurrent variceal bleeding, ascites, and hepatic encephalopathy. Discount rates of 3% for utilities and costs and a cost-effectiveness threshold of €25,000 per QALY were applied. RESULTS: In the base case analysis, TIPSS was estimated to be cost-effective as a pre-emptive treatment for indication 1 (incremental cost and QALYs of − €230 and 0.211, respectively). TIPSS also remained cost-effective (€16,819/QALY) in a conservative scenario analysis, conducted with an alternate source for clinical parameters. The key drivers of the outcomes were survival for the comparator arm, mean band ligation outpatient procedures, and TIPSS treatment costs. TIPSS was estimated to dominate the comparator for indication 2 (incremental cost and QALYs of − €25,687 and 0.531, respectively). The key drivers of the outcomes were monthly paracentesis sessions and cost per inpatient stay for those undergoing paracentesis. CONCLUSIONS: TIPSS is likely to be a cost-effective and a cost-saving treatment in patients with cirrhosis in indications 1 and 2, compared with standard treatments. The analyses estimate clinical benefits along with reduced healthcare costs from avoided downstream resource consumption. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02517-x. Springer Healthcare 2023-05-09 2023 /pmc/articles/PMC10272260/ /pubmed/37160834 http://dx.doi.org/10.1007/s12325-023-02517-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Bañares, Rafael
Albillos, Agustín
Nakum, Mitesh
Gea, Salvador
Varghese, Angel
Green, William
An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
title An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
title_full An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
title_fullStr An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
title_full_unstemmed An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
title_short An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
title_sort economic analysis of transjugular intrahepatic portosystemic covered stent shunt for variceal bleeding and refractory ascites in a spanish setting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272260/
https://www.ncbi.nlm.nih.gov/pubmed/37160834
http://dx.doi.org/10.1007/s12325-023-02517-x
work_keys_str_mv AT banaresrafael aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT albillosagustin aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT nakummitesh aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT geasalvador aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT vargheseangel aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT greenwilliam aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT banaresrafael economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT albillosagustin economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT nakummitesh economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT geasalvador economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT vargheseangel economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting
AT greenwilliam economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting